Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

Ab­b­Vie is walk­ing away from an ex­clu­sive op­tion for Har­poon’s BC­MA-tar­get­ing T cell en­gager for mul­ti­ple myelo­ma, leav­ing the Cal­i­for­nia com­pa­ny to ad­vance the as­set alone.

The agree­ment will end on Oct. 12, af­ter which the drug, HPN217, will be ful­ly owned by Har­poon. The biotech said it would com­plete an on­go­ing Phase I tri­al of the as­set in re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma with in­ter­im da­ta to be pre­sent­ed at the an­nu­al In­ter­na­tion­al Myelo­ma So­ci­ety meet­ing on Sept. 28, with an eye to sup­port­ing fur­ther de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER